ALX Oncology Holdings Inc. $ALXO Shares Acquired by venBio Partners LLC

venBio Partners LLC lifted its stake in ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 32.8% during the first quarter, Holdings Channel reports. The institutional investor owned 12,884,638 shares of the company’s stock after acquiring an additional 3,184,713 shares during the quarter. ALX Oncology makes up approximately 9.2% of venBio Partners LLC’s investment portfolio, making the stock its 3rd largest position. venBio Partners LLC owned about 0.10% of ALX Oncology worth $25,834,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ALXO. Orbimed Advisors LLC purchased a new position in ALX Oncology during the first quarter valued at approximately $5,747,000. Ameriprise Financial Inc. purchased a new stake in ALX Oncology in the 3rd quarter worth approximately $1,195,000. Renaissance Technologies LLC boosted its position in ALX Oncology by 73.2% in the 1st quarter. Renaissance Technologies LLC now owns 732,599 shares of the company’s stock worth $1,469,000 after purchasing an additional 309,500 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of ALX Oncology during the 2nd quarter worth approximately $84,000. Finally, Acadian Asset Management LLC grew its stake in shares of ALX Oncology by 16.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock worth $806,000 after purchasing an additional 186,883 shares during the period. 97.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ALXO. Weiss Ratings reiterated a “sell (d-)” rating on shares of ALX Oncology in a research note on Friday, June 26th. Wall Street Zen upgraded shares of ALX Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $4.60.

ALX Oncology Price Performance

Shares of NASDAQ ALXO opened at $2.02 on Tuesday. The firm has a market cap of $271.82 million, a PE ratio of -1.36 and a beta of 0.42. The firm has a fifty day moving average of $1.88 and a 200 day moving average of $1.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.21 and a current ratio of 7.21. ALX Oncology Holdings Inc. has a one year low of $0.51 and a one year high of $2.66.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). As a group, research analysts predict that ALX Oncology Holdings Inc. will post -0.66 EPS for the current fiscal year.

About ALX Oncology

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.